TG Therapeutics Announces Topline Results From UNITY-CLL Phase 3 Study Evaluating Combination Of Umbralisib And Ublituximab For Patients With Chronic Lymphocytic Leukemia; Trial Met Primary Endpoint
Benzinga Newsdesk